Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Liver Cirrhosis, Sarcopenia
Interventions: LPCN 1148, Placebo; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 6 more

Conditions: Angina, Stable Ischemic Heart Disease
Interventions: Clinician Discretion, Beta blocker, Calcium channel blocker; Other · Drug
Lead sponsor: Yale University; Other
Eligibility: 65 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 10
States / cities: New Haven, Connecticut • Marietta, Georgia • Chicago, Illinois + 5 more

Conditions: Primary Progressive Multiple Sclerosis, Hemiparesis
Interventions: Gaming CI Therapy; Behavioral
Lead sponsor: University of Massachusetts, Lowell; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Cancer, Brain Metastases
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: Cooper Norcross Health; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions: Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more

Conditions: Chronic Low-back Pain
Interventions: Cooled Radiofrequency, Conventional Radiofrequency; Device
Lead sponsor: Avanos Medical; Other
Eligibility: 21 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Bloomington, Illinois • New Orleans, Louisiana + 7 more

Conditions: Osteoarthritis
Interventions: Buprenorphine transdermal delivery system; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1999
U.S. locations: 10
States / cities: Huntsville, Alabama • Phoenix, Arizona • Westminster, Colorado + 6 more

Conditions: Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Cholestasis
Interventions: Placebo, GSK2330672; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Sacramento, California • Miami, Florida + 6 more

Conditions: Chronic Lymphocytic Leukemia, Lymphoma, Multiple Myeloma
Interventions: Plerixafor; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Analgesia
Interventions: KP-1199, Placebo oral capsule, Oxycodone oral capsule; Drug
Lead sponsor: Kalyra Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes Mellitus, Chronic Disease
Interventions: ECHO program for DMMC, Usual care; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Santa Fe, New Mexico

Conditions: Contraception, Adolescent Behavior, Emergency Department
Interventions: Multi-Level Intervention, Enhanced Standard of Care; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 15 Years to 18 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Kansas City, Missouri • Philadelphia, Pennsylvania

Conditions: Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Interventions: Barzolvolimab, Matching Placebo; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more

Conditions: Severe Sepsis
Interventions: AZD9773 (CytoFab), Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Newark, Delaware • Bay Pines, Florida + 23 more

Conditions: Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions: Etripamil, Placebo; Drug
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Phoenix, Arizona • Sacramento, California • Littleton, Colorado + 19 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
Interventions: Placebo, Bardoxolone Methyl (RTA 402); Other · Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 42
States / cities: Birmingham, Alabama • Montgomery, Alabama • Chula Vista, California + 36 more

Conditions: Multiple Sclerosis, Progressive
Interventions: Amniotic fluid or placental CD117 stem cells; Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Liso-cel, Idelalisib, Rituximab, Bendamustine, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 16
States / cities: Gilbert, Arizona • Duarte, California • Sacramento, California + 13 more

Conditions: Down Syndrome, Aneuploidy
Interventions: Maternal blood draw of 30 to 50ml; Other
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 10
States / cities: Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 3 more

Conditions: Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer, Colorectal Cancer
Interventions: LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel; Drug
Lead sponsor: PureTech; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Sarasota, Florida + 6 more

Conditions: Purpura, Thrombocytopenic, Idiopathic
Interventions: BI 655064; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Peripheral Vascular Disease
Interventions: Absolute Pro™ Peripheral Self-Expanding Stent System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Anesthesia
Interventions: Not listed
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 5 Years to 15 Years
Enrollment: 1,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Denver, Colorado • Atlanta, Georgia • Ann Arbor, Michigan

Search by objective public record fields.

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis

Stereotactic Radiosurgery (SRS) for Multiple CNS Mets

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Cooled RFA vs Conventional RFA to Manage Chronic Facetogenic Low Back Pain

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199

ECHO for Diabetes and Multiple Chronic Conditions Study

Reducing Adolescent Pregnancy in the Emergency Department

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

AZD9773 Dose Escalation Study

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.

CARE--Childhood Awareness and Recall Evaluation